Serum Insulin-like Growth Factor-Binding Protein-2 as a Prognostic Factor for COVID-19 Severity

Serum Insulin-like Growth Factor-Binding Protein-2 as a Prognostic Factor for COVID-19 Severity

Blog Article

Insulin-like growth factor-binding protein (IGFBP)-2 is a regulator of anabolic pathways, which become inactivated in severe illness.Here, we measured the serum IGFBP-2 levels of COVID-19 patients with moderate and severe disease as Cot well as healthy controls to identify the associations of serum IGFBP-2 levels with disease severity.Patients with severe COVID-19 had higher serum IGFBP-2 levels than those with moderate disease and healthy controls, who had similar levels.Non-survivors of COVID-19 tended to have elevated serum IGFBP-2 levels compared to survivors.Increased serum IGFBP-2 levels were observed in patients requiring dialysis and vasopressor therapy.

Serum IGFBP-2 was positively correlated with procalcitonin in both patient groups.Bacterial co-infection in severe COVID-19 patients did Wine Cabinet not influence serum IGFBP-2 levels.Patients with liver cirrhosis and obesity, showing increased and decreased serum IGFBP-2 levels, respectively, were excluded from the study.The present analysis showed that higher serum IGFBP-2 levels are associated with increased disease severity in COVID-19 patients.The similarity in serum IGFBP-2 levels between patients with moderate COVID-19 and healthy controls suggests that elevated IGFBP-2 is associated with critical illness rather than SARS-CoV-2 infection itself.